ERK/p38 MAPK inhibition reduces radio-resistance to pulsed proton beam in breast cancer stem cells cells

Recent studies have identified highly tumorigenic cells with stem cell-like characteristics in human cancers, termed cancer stem cells (CSCs). CSCs are resistant to conventional radiotherapy and chemotherapy owing to their high DNA repair ability and oncogene overexpression. However, the mechanisms regulating CSC radio-resistance, particularly proton beam resistance, remain unclear. We isolated CSCs from the breast cancer cell lines MCF-7 and MDA-MB-231, which expressed the characteristic breast CSC membrane protein markers CD44/CD24, and irradiated the CSCs with pulsed proton beams. We confirmed that CSCs are resistant to pulsed proton beams and showed that treatment with p38 and ERK inhibitors reduced CSC radioresistance. Based on these results, BCSC radio-resistance can be reduced during proton beam therapy by co-treatment with ERK1/2 or p38 inhibitors, representing a novel approach for breast cancer therapy.